Synaffix/LanzaElevation Oncology Inc has inked a US$368m license agreement with Lonza subsidiary Synaffix BV under which Synaffix will link Elevation’s HER3 antibody seribantumab to a monomethyl auristatin E (MMAE) toxic payload with broad therapeutic index.
Tag Archive for: Lonza
ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
To improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA products
Sotio hsd licenced Synaffix ADC platform for up to US$740m to develop up to three next generation bioconjugates.
Asher Biotherapeutics Inc has expanded its manufacturing agreement with Lonza to include the manufacturing of AB248.